Biotherapy Treatment on Features of Microcrystalline Polyarthritis (FUMBLE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04005625|
Recruitment Status : Recruiting
First Posted : July 2, 2019
Last Update Posted : July 8, 2019
The study will involve adult patient who had received any biologic agent for microcrystalline disease in western France (Tours, Le Mans, Orléans, Angers, Rennes, Poitiers et Brest) between 01/01/2010 and 31/12/2018.
Investigators will answer retrospectively a questionnaire that covers patient and disease data, biologic agent use, efficacy and adverse events.
|Condition or disease|
This is a retrospective multicentric study of all patients treated by biologic for microcrystalline disease in France in western France (Tours, Le Mans, Nantes, La Roche sur Yon, Orléans, Angers, Rennes, Poitiers et Brest) between 01/01/2010 and 31/12/2018.
The investigators will collect all clinical (diagnosis of gout CCPD or hydroxyapatitis, tender and swollen joint count), biological (blood results: ESR, CRP, uric acid, synovial analysis), radiological data (X-rays performed and their description) .
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Features of Microcrystalline Polyarthritis Treated by Biologics and Evolution - FUMBLE Study|
|Actual Study Start Date :||March 28, 2019|
|Estimated Primary Completion Date :||March 28, 2021|
|Estimated Study Completion Date :||June 20, 2021|
- Treatment duration [ Time Frame: one year ]Duration of treatment by biologic in days
- number of synovitis [ Time Frame: inclusion ]number of synovitis on 44
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04005625
|Contact: Alain SARAUX, MD, PhD||2 98347267 ext firstname.lastname@example.org|
|CHRU de Brest||Recruiting|
|Contact: Alain Saraux email@example.com|
|Principal Investigator:||Alain SARAUX, MD, PhD||CHU Brest|